Pharmaceuticals News and Research

RSS

FDA approves Teva's generic Effexor XR antidepressant

Teva Pharmaceutical Industries Ltd. announced today U.S. Food and Drug Administration (FDA) approval of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. Shipment is expected to commence on July 1, 2010, as per the terms of the 2006 agreement with Wyeth.

29 Jun 2010

Hospira announces intention to complete tender offer for Javelin's outstanding common stock shares

Hospira, Inc., a global specialty pharmaceutical and medication delivery company, today announced its intention to complete the tender offer by Discus Acquisition Corporation, a wholly owned Hospira subsidiary, for all outstanding shares of the common stock of Javelin Pharmaceuticals, Inc., upon its currently scheduled expiration at 12:00 midnight, New York City time, on June 30, 2010 (the end of the day on June 30, 2010).

29 Jun 2010

APP to market Anastrozole 1 mg tablets in U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited.

29 Jun 2010

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

BioAlliance Pharma SA, a company dedicated to the supportive care and treatment of cancer patients, has presented 2 abstracts on Loramyc® and clonidine Lauriad® at the MASCC/ISOO 2010 International Symposium (Vancouver, June 24-26, 2010). These two products belong to the supportive care pipeline of BioAlliance Pharma.

29 Jun 2010

World's leading pharma services industry events to held at Frankfurt in 2011

Leading events organiser UBM International Media today announced that its flagship CPhI Worldwide tradeshow will return to Frankfurt, Germany for 2011. Along with co-hosted events - P-MEC Europe for equipment, machinery and technology; ICSE for contract services and packaging; and BioPh Europe for the biopharma sector - the world's leading pharma services industry events will be held at Messe Frankfurt, from Tuesday 25 to Thursday 27 October.

28 Jun 2010

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

Tarix Pharmaceuticals today announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).

28 Jun 2010

Rexahn announces $10 million registered direct offering

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced it has received commitments from certain institutional investors to purchase an aggregate of $10 million of Rexahn's securities in a registered direct offering.

28 Jun 2010

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

ULURU Inc. announced today that Strakan International Limited and ULURU have divested their respective interest in Zindaclin® to a subsidiary of Crawford Healthcare Limited, a pharmaceutical company based in England. Zindaclin® is a product for the treatment of acne which is outside the strategic focus of ULURU. This product was included in the technology package ULURU acquired when it was formed in 2005.

28 Jun 2010

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Zeria Pharmaceutical announced today positive results of their Japanese Phase III study of Z-338 (acotiamide hydrochloride hydrate; "acotiamide") for the treatment of functional dyspepsia (FD). FD is a gastrointestinal disease comprised of subjective symptoms including postprandial fullness, early satiation and epigastric pain without any organic abnormality on gastrointestinal tract.

28 Jun 2010

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has signed a licensing agreement with the international pharmaceutical company Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed's anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia.

28 Jun 2010

Fate Therapeutics recognized with Red Herring's North America 100 award

Fate Therapeutics, Inc. announced today that the Company received Red Herring's North America 100 award, a prestigious list honoring the year's most promising private and innovative companies from the North American business region. The nominees were evaluated by the Red Herring editorial team on both quantitative and qualitative criteria, such as financial performance, technology innovation, quality of management, execution of strategy and integration into their respective industries.

28 Jun 2010

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Pain Therapeutics, Inc. announced today a modification of its strategic alliance with King Pharmaceuticals, Inc. for REMOXY outside the U.S. The move signals a desire to target Europe's small and growing market for strong pain medications.

28 Jun 2010

BioSante joins Russell 3000 Index

BioSante Pharmaceuticals, Inc. today announced it has been added to the broad-market Russell 3000 Index as part of Russell Investments' recent reconstitution of its comprehensive set of U.S. and global equity indexes which occurred after market close on June 25, 2010.

28 Jun 2010

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

MorphoSys AG and US-based biopharmaceutical company Xencor, Inc., announced today the signing of a worldwide exclusive license and collaboration agreement for an antibody in Phase 1 clinical development. The agreement provides MorphoSys with an exclusive worldwide license to XmAb5574, a high potency monoclonal antibody developed by Xencor for the treatment of B-cell malignancies.

28 Jun 2010

Clinical study results show no increased risk of CV events associated with SYMLIN injection

Amylin Pharmaceuticals, Inc. today announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular events associated with SYMLIN (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today presented an analysis of baseline data from the Phase 3 DEFEND-1 clinical trial of otelixizumab in patients with autoimmune new onset type 1 diabetes.

28 Jun 2010

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA (exenatide) injection added to Lantus (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

Tolerx, Inc., a biopharmaceutical company developing novel therapies to treat autoimmune diseases and cancer by modulating T cell activity, today announced the initiation of a confirmatory Phase 3 clinical trial to further evaluate otelixizumab in autoimmune new-onset type 1 diabetes. The confirmatory Phase 3 clinical trial is called DEFEND-2 (Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes) and immediately follows successful completion of enrollment in the initial Phase 3 clinical trial, DEFEND-1, with results from DEFEND-1 expected in the first half of 2011.

28 Jun 2010

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Soligenix, Inc., a late-stage biopharmaceutical company, announced today the publication of an article in the June 2010 edition of Vaccine, which describes protection from mucosal and systemic ricin intoxication by intradermal administration of RiVax™, the Company's vaccine against ricin toxin.

28 Jun 2010

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Raptor Pharmaceutical Corp. announced that it has enrolled the first patient in a pivotal Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ("DR Cysteamine") in patients with nephropathic cystinosis ("cystinosis").

28 Jun 2010

Pharmaceuticals News and Research

FDA approves Teva's generic Effexor XR antidepressant

Hospira announces intention to complete tender offer for Javelin's outstanding common stock shares

APP to market Anastrozole 1 mg tablets in U.S.

BioAlliance Pharma presents abstracts on Loramyc, clonidine Lauriad at MASCC/ISOO 2010 symposium

World's leading pharma services industry events to held at Frankfurt in 2011

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

Rexahn announces $10 million registered direct offering

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

Zeria reports positive results from Japanese Phase III study of Z-338 for functional dyspepsia

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Fate Therapeutics recognized with Red Herring's North America 100 award

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

BioSante joins Russell 3000 Index

MorphoSys, Xencor sign worldwide exclusive license, collaboration agreement for XmAb5574 antibody program

Clinical study results show no increased risk of CV events associated with SYMLIN injection

Tolerx presents data from otelixizumab Phase 3 DEFEND-1 clinical trial in type 1 diabetes patients

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Tolerx initiates confirmatory Phase 3 clinical trial to evaluate otelixizumab in new-onset type 1 diabetes

RiVax intradermal administration protects from mucosal, systemic ricin intoxication

Raptor initiates enrollment in pivotal Phase 3 clinical trial of DR Cysteamine for nephropathic cystinosis

Oxygen Measurement eBook - Easily Understand Dissolved Oxygen Measurement eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence